{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-022153","form_type":"8-K","ticker":"COCP","cik":"0001412486","company_name":"Cocrystal Pharma, Inc.","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.924602+00:00","generated_at":"2026-05-17T20:34:56.151670+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Cocrystal Pharma: Phase 1 CDI-988 well tolerated; Phase 1b planned for norovirus","bullets":["All CDI-988 doses (100-1200 mg) well tolerated in Phase 1 SAD and MAD cohorts; no severe AEs.","Treatment-emergent AEs in SAD: 28% (10/36) CDI-988 vs 40% (4/10) placebo; MAD: 53% (19/36) vs 92% (11/12).","Company expects to initiate Phase 1b challenge study in norovirus-infected healthy subjects later in 2025.","Headache most common AE; no clinically relevant ECG changes or pathology results reported.","CDI-988 targets 3CL viral proteases; potential prophylaxis/treatment for norovirus and coronaviruses."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-022153","json":"https://secwatch.observer/filing/0001641172-25-022153.json","markdown":"https://secwatch.observer/filing/0001641172-25-022153.md","text":"https://secwatch.observer/filing/0001641172-25-022153.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1412486/000164117225022153/0001641172-25-022153-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1412486/000164117225022153/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T20:34:56.151670+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}